EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hyperbaric Oxygen Therapy for Necrotizing Soft Tissue Infections: A Retrospective Cohort Analysis of Clinical Outcomes

Akira Shishido iD, Gregory Schrank, Alexander Vostal, Megan Uehling, Ravi Tripathi, Sai Chintalapati, Lauren Conway, Nikki Kus, Laura DiChiacchio, Marc Kai, Joseph A Kufera, Ronald Rabinowitz

Surgical Infections · 2025

DOI: 10.1089/sur.2024.285 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Surgical Infections, 2025. Verfasst von Akira Shishido und 11 weiteren Autor:innen. Beteiligte Einrichtung: University of Maryland School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Hyperbaric Oxygenation, Soft Tissue Infections, Fasciitis, Necrotizing. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hyperbaric oxygen therapy (HBOT) is an adjunctive therapy for necrotizing soft tissue infections (NSTIs) that remains controversial due to lack of quality clinical evidence. This retrospective cohort examines the impact of HBOT on clinical outcomes from NSTI at a single center where evaluation for HBOT is standard of care.

Methods

The COVID-19 pandemic disrupted HBOT service and NSTI cases went without HBOT treatment, allowing for a comparison of treatment groups. The clinical outcomes of 253 patients with NSTI that were evaluated for HBOT were compared; 143 (56.3%) received HBOT and 110 (43.3%) did not.

Results

Baseline characteristics were similar except for surface area of the wounds and distribution on the extremities. More patients in the non-HBOT group died within 90 days of admission than those in the HBOT group (5.8% vs. 15.4%, p = 0.015). Further, patients with large wounds (≥450 cm 2 ) and those with high APACHE II scores (≥18) who underwent HBOT had significantly lower risk of death than patients who did not (odds ratio [OR] 0.12, 95% confidence interval [CI] 0.02–0.72).

Conclusion

Our study shows that there was a mortality benefit in patients with NSTI that was more significant in patients with large wounds and higher APACHE II scores.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperbaric OxygenationSoft Tissue InfectionsFasciitis, NecrotizingHumansRetrospective StudiesMaleFemaleMiddle AgedAgedTreatment OutcomeCOVID-19AdultNecrosisSARS-CoV-2

Stichwörter der Autor:innen

hyperbaric oxygen therapynecrotizing fasciitis

Autor:innen und Institutionen

  • University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • National Study Center for Trauma and Emergency Medical Systems, Center for Shock, Trauma and Anesthesiology Research, Baltimore, Maryland, USA.

ORCID-Profile: Akira Shishido

Zitieren

APA

Shishido, A., Schrank, G., Vostal, A., Uehling, M., Tripathi, R., Chintalapati, S., Conway, L., Kus, N., DiChiacchio, L., Kai, M., Kufera, J. A., & Rabinowitz, R. (2025). Hyperbaric Oxygen Therapy for Necrotizing Soft Tissue Infections: A Retrospective Cohort Analysis of Clinical Outcomes. Surgical Infections. https://doi.org/10.1089/sur.2024.285

Vancouver

Shishido A, Schrank G, Vostal A, Uehling M, Tripathi R, Chintalapati S, et al. Hyperbaric Oxygen Therapy for Necrotizing Soft Tissue Infections: A Retrospective Cohort Analysis of Clinical Outcomes. Surgical Infections. 2025. doi:10.1089/sur.2024.285

BibTeX
@article{Shishido2025,
  author = {Shishido, Akira and Schrank, Gregory and Vostal, Alexander and Uehling, Megan and Tripathi, Ravi and Chintalapati, Sai and Conway, Lauren and Kus, Nikki and DiChiacchio, Laura and Kai, Marc and Kufera, Joseph A and Rabinowitz, Ronald},
  title = {Hyperbaric Oxygen Therapy for Necrotizing Soft Tissue Infections: A Retrospective Cohort Analysis of Clinical Outcomes},
  journal = {Surgical Infections},
  year = {2025},
  doi = {10.1089/sur.2024.285}
}
Kostenlos starten →